Syndax Pharmaceuticals, Inc. () reported earnings of ($0.68) per share beating Walls Streets expectations.

0

Syndax Pharmaceuticals, Inc. () reported Q3 2017 earnings this Afternoon, coming in at ($0.68) per share, beating Wall Street’s estimates of ($0.80) per Share. Revenue for the quarter came in at $0.31 million beating analyst estimates of $0.30 million

Analyst Coverage For Syndax Pharmaceuticals, Inc. ()
These are 0 Sell Ratings, 0 Hold Ratings, 9 Buy Ratings, 0 Strong Buy Ratings .
The current consensus rating for Syndax Pharmaceuticals, Inc. () is Buy (Score: 3.00) with a consensus target price of $24.29 , a potential (126.97% upside)

Recent Insider Trading for Syndax Pharmaceuticals, Inc. ()

  • On 5/17/2017 Peter Ordentlich, Insider, sold 5,000 with an average share price of $15.00 per share and the total transaction amounting to $75,000.00.
  • On 3/8/2016 Ivor Royston, Director, bought 150,000 with an average share price of $12.00 per share and the total transaction amounting to $1,800,000.00.



    Recent Trading for Syndax Pharmaceuticals, Inc. ()
    Shares of Syndax Pharmaceuticals, Inc. closed the previous trading session at with shares trading hands.

    An ad to help with our costs